[{"id":"f548789f-e984-493e-8c25-7196761bc8df","acronym":"","url":"https://clinicaltrials.gov/study/NCT07153952","created_at":"2025-09-06T13:40:49.515Z","updated_at":"2025-09-06T13:40:49.515Z","phase":"Phase 1/2","brief_title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","source_id_and_acronym":"NCT07153952","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-09-04"},{"id":"62ace1f9-004a-49d4-93f7-a7a0fc5fb5bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02531932","created_at":"2021-02-22T06:52:40.461Z","updated_at":"2025-02-25T14:00:45.845Z","phase":"Phase 2","brief_title":"Comparison of Single-Agent Carboplatin Vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02531932","lead_sponsor":"Amy Tiersten","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • everolimus"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/19/2024","study_completion_date":" 10/19/2024","last_update_posted":"2025-02-19"},{"id":"18460073-b219-4680-b839-36cecdb58964","acronym":"CALGB-40601","url":"https://clinicaltrials.gov/study/NCT00770809","created_at":"2021-01-17T17:29:01.763Z","updated_at":"2025-02-25T16:36:00.390Z","phase":"Phase 3","brief_title":"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT00770809 - CALGB-40601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 305","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 01/31/2014","primary_completion_date":" 01/31/2014","study_txt":" Completion: 07/10/2025","study_completion_date":" 07/10/2025","last_update_posted":"2025-02-06"},{"id":"8558f5f4-3c34-4ca5-977c-ce483a267ebe","acronym":"","url":"https://clinicaltrials.gov/study/NCT06811220","created_at":"2025-02-25T16:50:25.446Z","updated_at":"2025-02-25T16:50:25.446Z","phase":"Phase 3","brief_title":"The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients","source_id_and_acronym":"NCT06811220","lead_sponsor":"Alexandria University","biomarkers":" TNFA • IL1B","pipe":"","alterations":" ","tags":["TNFA • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 01/27/2025","start_date":" 01/27/2025","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-06"},{"id":"8a36dc46-7e94-43f5-8360-2cd36c81ca39","acronym":"","url":"https://clinicaltrials.gov/study/NCT04034251","created_at":"2021-01-18T19:47:54.419Z","updated_at":"2025-02-25T17:00:07.598Z","phase":"Phase 2","brief_title":"Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis","source_id_and_acronym":"NCT04034251","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 02/25/2023","primary_completion_date":" 02/25/2023","study_txt":" Completion: 09/05/2024","study_completion_date":" 09/05/2024","last_update_posted":"2025-02-03"},{"id":"9d3a2345-4750-430f-b35f-e0833cfd90c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06042569","created_at":"2023-09-18T14:40:16.409Z","updated_at":"2025-02-25T17:39:21.068Z","phase":"Phase 2","brief_title":"Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial","source_id_and_acronym":"NCT06042569","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 09/16/2024","start_date":" 09/16/2024","primary_txt":" Primary completion: 03/20/2028","primary_completion_date":" 03/20/2028","study_txt":" Completion: 03/20/2028","study_completion_date":" 03/20/2028","last_update_posted":"2025-01-29"},{"id":"739da834-c39c-4ec9-a53c-9176d039bf87","acronym":"WSG-ADAPT-TN","url":"https://clinicaltrials.gov/study/NCT01815242","created_at":"2021-01-18T08:03:29.975Z","updated_at":"2025-02-25T14:34:04.747Z","phase":"Phase 2","brief_title":"Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer","source_id_and_acronym":"NCT01815242 - WSG-ADAPT-TN","lead_sponsor":"West German Study Group","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 336","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-11-20"},{"id":"0ce25812-d787-4958-871c-71452dd45f1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01446731","created_at":"2025-07-19T13:53:52.425Z","updated_at":"2025-07-19T13:53:52.425Z","phase":"Phase 2","brief_title":"Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer","source_id_and_acronym":"NCT01446731","lead_sponsor":"Inge Marie Svane","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2024-07-03"},{"id":"5ef966bd-a434-424a-a96e-8afc658d0dee","acronym":"ECOG-ACRIN EAZ171","url":"https://clinicaltrials.gov/study/NCT04001829","created_at":"2021-01-18T19:40:09.877Z","updated_at":"2025-02-25T13:52:56.517Z","phase":"Phase 2","brief_title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","source_id_and_acronym":"NCT04001829 - ECOG-ACRIN EAZ171","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 08/09/2019","start_date":" 08/09/2019","primary_txt":" Primary completion: 09/19/2023","primary_completion_date":" 09/19/2023","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2024-06-25"},{"id":"f3d782d2-7f3d-4ad2-b8d5-99602c17c34a","acronym":"SONOBIRD","url":"https://clinicaltrials.gov/study/NCT05902169","created_at":"2023-06-13T17:08:12.284Z","updated_at":"2024-07-02T16:34:26.706Z","phase":"Phase 3","brief_title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","source_id_and_acronym":"NCT05902169 - SONOBIRD","lead_sponsor":"CarThera","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • IDH1 R132H • IDH1 R132","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • lomustine"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 01/29/2024","start_date":" 01/29/2024","primary_txt":" Primary completion: 01/28/2028","primary_completion_date":" 01/28/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-06-12"},{"id":"da3993b4-3224-43f3-abf3-1a2b44201eaf","acronym":"TINKS","url":"https://clinicaltrials.gov/study/NCT05634369","created_at":"2023-12-20T08:17:53.968Z","updated_at":"2024-07-02T16:34:37.915Z","phase":"Phase 1/2","brief_title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","source_id_and_acronym":"NCT05634369 - TINKS","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • dexamethasone • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-05"},{"id":"02e25d96-3ff3-4250-9821-ad530f91101e","acronym":"PEARLY","url":"https://clinicaltrials.gov/study/NCT02441933","created_at":"2021-01-18T11:41:58.115Z","updated_at":"2024-07-02T16:34:59.228Z","phase":"Phase 3","brief_title":"Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)","source_id_and_acronym":"NCT02441933 - PEARLY","lead_sponsor":"Yonsei University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 878","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"ba1ff799-4c96-4b36-abc9-9696cce6175e","acronym":"NCI-2018-01836","url":"https://clinicaltrials.gov/study/NCT00494182","created_at":"2021-01-18T01:46:04.063Z","updated_at":"2024-07-02T16:35:01.215Z","phase":"Phase 2","brief_title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","source_id_and_acronym":"NCT00494182 - NCI-2018-01836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1","pipe":" | ","alterations":" TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression","tags":["HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • sorafenib • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/25/2007","start_date":" 04/25/2007","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"42d098db-7735-4ec6-beca-081467347e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00254384","created_at":"2021-01-18T00:51:46.726Z","updated_at":"2024-07-02T16:35:01.822Z","phase":"Phase 1","brief_title":"Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery","source_id_and_acronym":"NCT00254384","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • erlotinib • docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/05/2005","start_date":" 10/05/2005","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2024-05-23"},{"id":"130d64cc-8174-4099-9fdc-c77e00468d6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02003209","created_at":"2021-01-18T09:08:50.149Z","updated_at":"2024-07-02T16:35:02.395Z","phase":"Phase 3","brief_title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT02003209","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" TILs","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • goserelin acetate • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 10/31/2016","primary_completion_date":" 10/31/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-21"},{"id":"7c21da8e-5d4d-49d2-b559-c9e8b999b515","acronym":"","url":"https://clinicaltrials.gov/study/NCT03987555","created_at":"2021-01-18T19:36:27.910Z","updated_at":"2024-07-02T16:35:06.257Z","phase":"","brief_title":"Paclitaxel Therapeutic Drug Monitoring in Cancer Patients","source_id_and_acronym":"NCT03987555","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2019","start_date":" 11/11/2019","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"},{"id":"4d2d76d4-435a-440f-8e0e-92bf66cb6dca","acronym":"NRG-GY019","url":"https://clinicaltrials.gov/study/NCT04095364","created_at":"2021-01-18T20:02:20.500Z","updated_at":"2024-07-02T16:35:06.502Z","phase":"Phase 3","brief_title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT04095364 - NRG-GY019","lead_sponsor":"NRG Oncology","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 expression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 09/20/2019","start_date":" 09/20/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-05-02"},{"id":"1903d6da-d5c7-43b4-a343-51787a604398","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070564","created_at":"2021-01-18T00:10:47.683Z","updated_at":"2024-07-02T16:35:09.760Z","phase":"Phase 3","brief_title":"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","source_id_and_acronym":"NCT00070564","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 amplification • ER negative • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 amplification • ER negative • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3294","initiation":"Initiation: 11/01/2003","start_date":" 11/01/2003","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-04-15"},{"id":"7d169331-b846-4d9b-bf64-50ab5cca40e6","acronym":"SWOG S2210","url":"https://clinicaltrials.gov/study/NCT05806515","created_at":"2023-04-10T14:03:16.793Z","updated_at":"2024-07-02T16:35:11.454Z","phase":"Phase 2","brief_title":"Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation","source_id_and_acronym":"NCT05806515 - SWOG S2210","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-04-04"},{"id":"282de3d0-8f82-4895-a112-bc0353a05ae5","acronym":"NSABP B-30","url":"https://clinicaltrials.gov/study/NCT00003782","created_at":"2021-01-17T22:53:06.131Z","updated_at":"2024-07-02T16:35:13.405Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes","source_id_and_acronym":"NCT00003782 - NSABP B-30","lead_sponsor":"NSABP Foundation Inc","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 5351","initiation":"Initiation: 03/01/1999","start_date":" 03/01/1999","primary_txt":" Primary completion: 12/01/2008","primary_completion_date":" 12/01/2008","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2024-03-21"},{"id":"0ac61cbf-3e9f-4af1-95a4-5ca408d4fa59","acronym":"NeoTRIPaPDL1","url":"https://clinicaltrials.gov/study/NCT02620280","created_at":"2021-01-18T12:43:52.463Z","updated_at":"2024-07-02T16:35:16.015Z","phase":"Phase 3","brief_title":"Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","source_id_and_acronym":"NCT02620280 - NeoTRIPaPDL1","lead_sponsor":"Fondazione Michelangelo","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Completed","enrollment":" Enrollment 278","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/07/2024","study_completion_date":" 01/07/2024","last_update_posted":"2024-03-06"},{"id":"eefc11d2-7d17-482f-99c4-05762968de03","acronym":"","url":"https://clinicaltrials.gov/study/NCT01982448","created_at":"2021-01-18T09:01:41.136Z","updated_at":"2024-07-02T16:35:16.209Z","phase":"Phase 2","brief_title":"Cisplatin vs Paclitaxel for Triple Negative Breast Cancer","source_id_and_acronym":"NCT01982448","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER • ALK • PGR • BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • HRD • PGR negative","tags":["HER-2 • ER • ALK • PGR • BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • HRD • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 08/01/2020","study_completion_date":" 08/01/2020","last_update_posted":"2024-03-06"},{"id":"68ee6666-a2a3-4022-9809-88a75276636f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04608409","created_at":"2024-03-01T20:31:47.689Z","updated_at":"2024-07-02T16:35:16.832Z","phase":"Phase 1","brief_title":"Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer","source_id_and_acronym":"NCT04608409","lead_sponsor":"Frederick R. Ueland, M.D.","biomarkers":" ABCB1","pipe":" | ","alterations":" ABCB1 expression","tags":["ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABCB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-01"},{"id":"dcac73c8-c1d0-482d-9cf9-984699bad66d","acronym":"ATHOC","url":"https://clinicaltrials.gov/study/NCT05490407","created_at":"2022-08-05T13:57:24.967Z","updated_at":"2024-07-02T16:35:21.852Z","phase":"","brief_title":"Role of the ATP7A Transporter in Ovarian Cancer","source_id_and_acronym":"NCT05490407 - ATHOC","lead_sponsor":"University Medical Centre Ljubljana","biomarkers":" ATP7A • CP","pipe":"","alterations":" ","tags":["ATP7A • CP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2024-01-30"}]